Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | USP5 | P45974 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12623892 | 0.85 | LMNA (0.46) | HSD11B1POLBSMN1; SMN2KMT2AUSP5 | |
| SCHEMBL12621853 | 0.77 | ALDH1A1 (0.48) | SMN1; SMN2MEN1KMT2ATSHRATM | |
| SCHEMBL17553231 | 0.76 | LIMK2 (0.39) | HSD11B1SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL12626337 | 0.74 | LSS (0.40) | HSD11B1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL12623927 | 0.73 | CYP19A1 (0.37) | HSD11B1KDM2BSMN1; SMN2ATM | |
| SCHEMBL12623903 | 0.73 | ALDH1A1 (0.45) | HSD11B1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1328129 | 0.67 | KDM4E (0.41) | HTR2AHTR2CMEN1KMT2ATSHR | |
| SCHEMBL12622104 | 0.66 | POLB (0.55) | POLB | |
| SCHEMBL20791736 | 0.63 | L3MBTL1 (0.51) | POLB | |
| SCHEMBL12626263 | 0.62 | ALDH1A1 (0.50) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | HSD11B1 3931/4885HTR2A 422/4885HTR2C 1538/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HSD11B1 3931/4885HTR2A 422/4885HTR2C 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.